Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients

被引:53
|
作者
Chen, Qingyong [1 ]
Fei, Jun [1 ]
Wu, Lijun [1 ]
Jiang, Zhongyong [1 ]
Wu, Yuquan [1 ]
Zheng, Yun [1 ]
Lu, Guohua [2 ]
机构
[1] 117th Hosp PLA, Dept Resp Dis, Hangzhou 310013, Zhejiang, Peoples R China
[2] Zhejiang Univ, Dept Resp Dis, Affiliated Hosp 1, Coll Med, Hangzhou 310004, Zhejiang, Peoples R China
关键词
cathepsin B; cathepsin L; cysteine C; urokinase plasminogen activator; urokinase plasminogen activator receptor; lung cancer; progonosis; sera; INHIBITORS STEFIN-A; PROGNOSTIC-SIGNIFICANCE; PULMONARY ADENOCARCINOMAS; CLINICAL-SIGNIFICANCE; CYSTEINE PROTEINASES; COLORECTAL-CANCER; EXPRESSION; METASTASIS; PROTEASES; PROGRESSION;
D O I
10.3892/ol.2011.302
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The present study aimed to determine the levels of cathepsin B (cath B), cathepsin L (cath L), cystatin C, urokinase plasminogen activator (u-PA) and urokinase plasminogen activator receptor (u-PAR) in the sera of patients with lung cancer compared to healthy controls using ELISA. Concomitantly, the relationship between the components and clinicopathological prognosis was analyzed. The study included 30 healthy volunteers and 105 lung cancer patients. Blood samples were collected and cath B, cath L, cystatin C, u-PA and u-PAR measurements were made using ELISA. Results showed that the levels of cath B, cath L, cystatin C, u-PA and u-PAR were significantly higher in the patient group compared to the healthy controls. The significance was marked for cath B and mild for u-PAR in correlation with lymph node metastasis. There was no significance for other parameters. Notably, patients with a combination of high cystatin C and high cath B levels had significantly lower survival probability as compared to those with cystatin C(+)/cath B(-) or with cystatin C(-)/cath B(-), Similarly, patients with a combination of high u-PA and u-PAR experienced significantly shorter survival., Furthermore, the univariate analysis revealed that cath B, u-PAR, lymph node metastases, stage and grade were related to survival. However, findings of the multivariate Cox analysis indicated that the sera levels of cath B, u-PAR and lymph node metastases may serve as independent prognostic variables in patients with lung cancer.
引用
收藏
页码:693 / 699
页数:7
相关论文
共 50 条
  • [21] Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B
    Zhou, Huanqin
    Wu, Xianguo
    Lu, Xingguo
    Chen, Gang
    Ye, Xiongwei
    Huang, Jian
    THROMBOSIS RESEARCH, 2009, 123 (03) : 537 - 542
  • [22] Soluble urokinase-type plasminogen activator receptor and urokinase-type plasminogen activator receptor contribute to chemoresistance in leukemia
    Guo, Hong
    Zhou, Lan-Xia
    Ma, Haizhen
    Liu, Bei
    Cheng, Juan
    Ma, Yun-Yun
    Zhao, Li
    ONCOLOGY LETTERS, 2017, 14 (01) : 383 - 389
  • [23] Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors
    Gutova, Margarita
    Najbauer, Joseph
    Frank, Richard T.
    Kendall, Stephen Edward
    Gevorgyan, Anna
    Metz, Marianne Z.
    Guevorkian, Mark
    Edmiston, Marissa
    Zhao, Donghong
    Glackin, Carlotta A.
    Kim, Seung U.
    Aboody, Karen S.
    STEM CELLS, 2008, 26 (06) : 1406 - 1413
  • [24] Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer
    Memarzedeh, S
    Kozak, KR
    Chang, L
    Natarajan, S
    Shintaku, P
    Reddy, ST
    Farias-Eisner, R
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (16) : 10647 - 10652
  • [25] Expression of urokinase type plasminogen activator receptor and plasminogen activator inhibitor-1 in gastric cancer
    Kawasaki, K
    Hayashi, Y
    Wang, Y
    Suzuki, S
    Morita, Y
    Nakamura, T
    Narita, K
    Doe, W
    Itoh, H
    Kuroda, Y
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1998, 13 (09) : 936 - 944
  • [26] The urokinase plasminogen activator receptor as a gene therapy target for cancer
    Pillay, Vinochani
    Dass, Crispin R.
    Choong, Peter F. M.
    TRENDS IN BIOTECHNOLOGY, 2007, 25 (01) : 33 - 39
  • [27] The urokinase-type plasminogen activator and its receptor in cancer
    Rosenberg, S
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 34, 1999, 34 : 121 - 128
  • [28] The role of urokinase type plasminogen activator receptor in colorectal cancer
    Herszenyi, L
    Farinati, F
    Plebani, M
    Carraro, P
    De Paoli, M
    Istvan, G
    Sapi, Z
    Naccarato, R
    Tulassay, Z
    GASTROENTEROLOGY, 1999, 116 (04) : A421 - A421
  • [29] Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer
    GrondahlHansen, J
    Peters, HA
    vanPutten, WLJ
    Look, MP
    Pappot, H
    Ronne, E
    Dano, K
    Klijn, JGM
    Brunner, N
    Foekens, JA
    CLINICAL CANCER RESEARCH, 1995, 1 (10) : 1079 - 1087
  • [30] Urokinase type plasminogen activator (UPA) and cathepsin B (CATB) plasma levels in gastro-intestinal tract cancer
    Farinati, F
    Foschia, F
    Cardin, R
    Plebani, M
    De Paoli, M
    Gianni, S
    Rinaldi, M
    Naccarato, R
    GASTROENTEROLOGY, 1999, 116 (04) : A400 - A400